Non-Invasive and Pharmacologic Approaches to Treating OAB

Behavioral interventions occupy a foundational role in overactive bladder (OAB) management, supported by a Grade A recommendation in the 2024 AUA/SUFU guideline and a growing body of evidence demonstrating additive benefit when combined with pharmacotherapy. In the second segment of this series, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES founder, Fosnight Center for Sexual Health in Asheville, North Carolina, discusses the evidence base and real-world implementation of bladder training, noting that the combination of bladder training and oral medication produces urge reduction in approximately 71% of patients, compared with 56% for medication alone—a clinically meaningful difference that she communicates transparently, alongside an honest accounting of the modest magnitude of effect on leakage episodes. Fosnight emphasizes that success with bladder training is contingent on adherence, and she structures the conversation around each patient's daily schedule, technology access, and realistic capacity for follow-through.

On pharmacologic therapy, Fosnight describes her longstanding practice of leading with beta-3 agonists rather than anticholinergics as an expression of her core clinical principle that any treatment must first be safe. The association between antimuscarinic medications and incident dementia—which may be cumulative and dose-dependent—was already well established before the 2024 guideline formally prioritized beta-3 agonists, and Fosnight indicates that the guideline's recommendation was confirmatory rather than directive for her. She emphasizes that this preference does not reflect a judgment that anticholinergics are never appropriate, but rather that the safety profile of beta-3 agonists, combined with comparable symptom control, makes them the logical default. Affordability and adverse-event tolerability are equally weighted considerations in her prescribing decisions.

Fosnight also addresses the guideline's provision allowing clinicians to offer minimally invasive therapies without requiring prior trials of behavioral or pharmacologic treatment, noting that in her practice the more common scenario is a patient who has already attempted first-line options before reaching her office. Rather than requiring patients to repeat a treatment course they have already undergone, she treats documented prior therapy as valid evidence and proceeds accordingly—a posture she frames as respecting patient experience and avoiding unnecessary delay. For patients who cannot tolerate medications, carry contraindications, or have values clearly oriented away from pharmacotherapy, she describes the option to bypass oral treatment as the most clinically appropriate and respectful path forward. When introducing minimally invasive options after 2 or more agents have not produced adequate improvement, she avoids the language of failure in favor of reframing the data: Each unsuccessful medication narrows the differential and points toward a different mechanism of action, opening space for curiosity rather than discouragement.